Supported by our findings (Figure S7) and studies indicating the synergistic anti-cancer effect of NAMPT inhibitors when treated with chemotherapeutic agents that cause peripheral neuropathies 24, 54, we conclude that the novel NAMPT inhibitor A4276 enhances chemotherapy and prevents neuropathy as a combinatorial cancer treatment against NAPRT-deficient cancers. The gene discussed is NAPRT; the disease is peripheral neuropathy.